119 related articles for article (PubMed ID: 2934581)
21. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
22. Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects.
Bergquist C; Nillius SJ; Wide L
Clin Endocrinol (Oxf); 1982 Jul; 17(1):91-8. PubMed ID: 6811167
[TBL] [Abstract][Full Text] [Related]
23. [Contraception by cyclic treatment with buserelin and progesterone].
Wieacker P; Breckwoldt M; Greif M; Geisthövel F
Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):135-9. PubMed ID: 1904039
[TBL] [Abstract][Full Text] [Related]
24. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
Lockwood GM; Pinkerton SM; Barlow DH
Hum Reprod; 1995 Feb; 10(2):293-8. PubMed ID: 7769051
[TBL] [Abstract][Full Text] [Related]
25. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
26. Luteinizing hormone releasing hormone analogues for contraception.
Nillius SJ
Clin Obstet Gynaecol; 1984 Dec; 11(3):551-72. PubMed ID: 6391776
[TBL] [Abstract][Full Text] [Related]
27. Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial.
Avrech OM; Goldman GA; Pinkas H; Amit S; Neri A; Zukerman Z; Ovadia J; Fisch B
Gynecol Endocrinol; 1996 Jun; 10(3):165-70. PubMed ID: 8862491
[TBL] [Abstract][Full Text] [Related]
28. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin).
Schriock E; Monroe SE; Henzl M; Jaffe RB
Fertil Steril; 1985 Nov; 44(5):583-8. PubMed ID: 2932349
[TBL] [Abstract][Full Text] [Related]
29. Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.
Schmidt-Sarosi C; Kaplan DR; Sarosi P; Essig MN; Licciardi FL; Keltz M; Levitz M
J Assist Reprod Genet; 1995 Mar; 12(3):167-74. PubMed ID: 8520180
[TBL] [Abstract][Full Text] [Related]
30. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; von der Ohe M; Nevinny-Stickel J
Contraception; 1981 Feb; 23(2):187-95. PubMed ID: 6786826
[TBL] [Abstract][Full Text] [Related]
31. Contraceptive properties of luteinising hormone releasing hormone.
Lambe RF; Werner-Zodrow I; Darragh A; Mall-Häfeli M
Lancet; 1979 Oct; 2(8146):801. PubMed ID: 90901
[TBL] [Abstract][Full Text] [Related]
32. Effect of gonadorelin, lecirelin, and buserelin on LH surge, ovulation, and progesterone in cattle.
Picard-Hagen N; Lhermie G; Florentin S; Merle D; Frein P; Gayrard V
Theriogenology; 2015 Jul; 84(2):177-83. PubMed ID: 25890780
[TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study.
El-Nemr A; Bhide M; Khalifa Y; Al-Mizyen E; Gillott C; Lower AM; Al-Shawaf T; Grudzinskas JG
Eur J Obstet Gynecol Reprod Biol; 2002 Jul; 103(2):140-5. PubMed ID: 12069736
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of the potential utility of LHRH agonists and antagonists for fertility control.
Vickery BH
J Steroid Biochem; 1985 Nov; 23(5B):779-91. PubMed ID: 3001420
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
Nillius SJ; Bergquist C; Wide L
Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
[TBL] [Abstract][Full Text] [Related]
36. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys.
Navot D; Rosenwaks Z; Anderson F; Hodgen GD
Fertil Steril; 1991 Jun; 55(6):1069-75. PubMed ID: 1828042
[TBL] [Abstract][Full Text] [Related]
37. Luteinizing-hormone-releasing hormone agonist treatment in patients with previously failed folliculogenesis during in vitro fertilization therapy.
MacLachlan V; Besanko M; Wade H; Morrow L; O'Shea F; Trounson A; Healy D
Ann N Y Acad Sci; 1988; 541():60-74. PubMed ID: 2973764
[No Abstract] [Full Text] [Related]
38. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
[TBL] [Abstract][Full Text] [Related]
39. Ultrasonic measurement of ovarian follicles during chronic LRH agonist treatment for contraception.
Bergquist C; Lindgren PG
Contraception; 1983 Aug; 28(2):125-33. PubMed ID: 6416744
[TBL] [Abstract][Full Text] [Related]
40. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
